Perspective Therapeutics (NYSEAMERICAN:CATX) Receives Outperform Rating from Wedbush

Wedbush reissued their outperform rating on shares of Perspective Therapeutics (NYSEAMERICAN:CATX) in a report released on Wednesday morning,Benzinga reports. They currently have a $11.00 target price on the stock.

Other equities analysts have also recently issued reports about the stock. Piper Sandler began coverage on shares of Perspective Therapeutics in a research note on Thursday, February 19th. They set an “overweight” rating and a $16.00 price target for the company. Truist Financial set a $12.00 price target on Perspective Therapeutics in a research report on Tuesday. Royal Bank Of Canada decreased their price objective on shares of Perspective Therapeutics from $18.00 to $14.00 and set an “outperform” rating on the stock in a report on Tuesday. B. Riley Financial lowered their target price on Perspective Therapeutics from $12.00 to $11.00 and set a “buy” rating on the stock in a research note on Tuesday, November 18th. Finally, UBS Group reaffirmed a “buy” rating and set a $7.00 price target (down from $18.00) on shares of Perspective Therapeutics in a research report on Friday, November 21st. One investment analyst has rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the stock. According to MarketBeat.com, Perspective Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $12.50.

Perspective Therapeutics Stock Down 1.8%

Shares of Perspective Therapeutics stock opened at $4.86 on Wednesday. The business has a 50-day moving average of $4.30 and a two-hundred day moving average of $3.43. Perspective Therapeutics has a 1 year low of $1.60 and a 1 year high of $6.16. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.66 and a current ratio of 5.17.

Perspective Therapeutics (NYSEAMERICAN:CATX) last announced its earnings results on Monday, March 16th. The company reported ($0.51) EPS for the quarter. Perspective Therapeutics had a negative return on equity of 41.79% and a negative net margin of 11,665.27%.The company had revenue of $0.04 million for the quarter. Analysts anticipate that Perspective Therapeutics will post -0.88 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. raised its position in Perspective Therapeutics by 5.0% during the 3rd quarter. Vanguard Group Inc. now owns 3,437,865 shares of the company’s stock worth $11,792,000 after purchasing an additional 163,532 shares during the last quarter. Avidity Partners Management LP increased its holdings in Perspective Therapeutics by 7.2% in the fourth quarter. Avidity Partners Management LP now owns 3,210,733 shares of the company’s stock worth $8,830,000 after purchasing an additional 216,700 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Perspective Therapeutics by 15.8% in the 2nd quarter. Geode Capital Management LLC now owns 1,382,814 shares of the company’s stock valued at $4,758,000 after acquiring an additional 188,887 shares in the last quarter. Opaleye Management Inc. acquired a new position in shares of Perspective Therapeutics during the fourth quarter valued at about $3,257,000. Finally, State Street Corp raised its stake in Perspective Therapeutics by 3.3% during the 4th quarter. State Street Corp now owns 1,141,247 shares of the company’s stock worth $3,138,000 after buying an additional 36,543 shares during the period. Institutional investors own 54.66% of the company’s stock.

More Perspective Therapeutics News

Here are the key news stories impacting Perspective Therapeutics this week:

• Positive Sentiment: B. Riley raised its price target from $11 to $13 and maintained a “Buy” rating — a sizeable upside projection that signals stronger sell‑side conviction in the company’s growth/clinical roadmap. B. Riley Price Target Raise
• Positive Sentiment: UBS raised its price target from $7 to $8 and kept a “Buy” rating, providing additional analyst support for upside potential. UBS Price Target Raise
• Positive Sentiment: Wedbush reaffirmed its “Outperform” rating with an $11 target — another vote of confidence from a major biotech analyst. Wedbush Rating Reaffirmation
• Positive Sentiment: Perspective announced that updated data for its lead radiopharmaceutical, [212Pb]VMT-α-NET, was accepted for poster presentation at AACR 2026 — this raises scientific visibility and could help commercial/regulatory momentum if the data remain favorable. The company previously reported encouraging anti‑tumor activity (76% without progression in a subset) and no dose‑limiting toxicities in interim analyses. AACR Presentation Acceptance
• Neutral Sentiment: The company is scheduled to release quarterly earnings this week — an event that can be a catalyst for volatility as investors reassess cash runway, R&D spend and trial progress. Earnings Release Date
• Neutral Sentiment: Perspective published full‑year 2025 results and business highlights; these filings provide more detail on cash, operating burn and program timelines that investors will parse for runway and dilution risk. Full‑Year 2025 Results
• Negative Sentiment: Royal Bank of Canada trimmed its target from $18 to $14 (still “Outperform”) — a downward revision that could moderate upside expectations and trigger short‑term profit‑taking. RBC Target Lowered
• Negative Sentiment: Clinical safety data include Grade 3+ treatment‑emergent adverse events in ~37.5% of patients (one transient Grade 4 reported); these safety signals may temper enthusiasm until larger cohorts and confirmatory data are available. Clinical Safety Details

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.